In July 2016 Boehringer Ingelheim Pharmaceuticals, Inc. received a Supplemental Approval letter from the FDA concerning a label change about fatal cases of ketoacidosis which have been reported concerning Jardiance, Synjardy, and Glyxambi. These relatively new diabetes medicines are part of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors … [Read more...]